内皮抑素及其在肿瘤治疗中的应用研究进展  

Current progression of endostar on clinical application and research

作　　者：王长林[1] 任明华[1] 

机构地区：[1]哈尔滨医科大学附属第一医院泌尿外科,150001

出　　处：《国际遗传学杂志》2010年第5期298-302,共5页International Journal of Genetics

基　　金：黑龙江省教育厅基金（11521188）

摘　　要：内皮抑素是一种内源性血管生成抑制因子,其能通过多种作用机制抑制血管内皮细胞迁移而抑制肿瘤血管生成,从而抑制肿瘤的生长,除此之外内皮抑素与放疗、化疗相结合效果显著,同时内皮抑素作为肿瘤的标志物,在利用特殊的给药系统进行治疗的研究上也有了突破性的进展.重组人血管内皮抑制素注射液（恩度）大大的提高内皮抑素的抗肿瘤作用,现已进入Ⅲ期临床研究,利用定点诱变技术得到的小分子内皮抑素不仅抑癌效果显著,并且纯化容易,可以低成本大量生产,为肿瘤的治疗提供了广阔的前景.本文就内皮抑素的结构特征、作用机制、在肿瘤治疗中的应用进展作一综述.Endostatin as an endogenous angiogenesis inhibitor can inhibit the tumor angiogenesis through the inhibition of vascular endothelial cell migration by variety of mechanisms, thereby inhibiting the growth of tumor. The effect of combination of endostatin, radiotherapy and chemotherapy is remarkable. In addition, endostatin as a tumor marker with special drug delivery systems has brought a breakthrough in treatment of tumor. Injection of recombinant human endostatin can enhance the anti-tumor effect greatly, and it has entered Phase Ⅲ experimental study. Small molecular endostatin can be purified easily by using the technology of site-directed mutagenesis. Not only can it low the cost of mass production, but also it can provide a broad prospect in the treatment of cancer. In this paper, we provide a review of the progress in the structure of endostatin,anti-tumnor mechanism and the application in cancer therapy.

关 键 词：内皮抑素 抗肿瘤 

分 类 号：R734.2[医药卫生—肿瘤]